AtriCure (NASDAQ:ATRC – Free Report) had its target price decreased by JPMorgan Chase & Co. from $51.00 to $46.00 in a ...

AtriCure (NASDAQ:ATRC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a research note issued to investors on Thursday,Benzinga reports.

Karen Prange, a director at $ATRC, sold 6,100 shares of the company on 03-05-2025 for an estimated $232,531. We received data on the trade from a recent SEC filing ...

AtriCure (ATRC) delivered earnings and revenue surprises of 46.67% and 0.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC – Research Report) and Journey ...

Barclays said in a note Monday that it sees attractive entry points in MedTech stocks, as recent weakness in some sector ...

AtriCure (ATRC) came out with a quarterly loss of $ ... The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will ...

Canaccord lowered the firm’s price target on AtriCure (ATRC) to $52 from $66 and keeps a Buy rating on the shares. The firm updated its model ...